ArticleElectrophoresis2026
Production and Purification of Mesenchymal Stem Cell-Derived Extracellular Vesicles Using Preferential Exclusion Chromatography.
Article in Electrophoresis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) therapeutics hold the potential to harness the regenerative power of their parental cells, promoting proliferation and reducing inflammation. There is a need for the production and isolation process that can be easily scaled and deliver the desired quality and quantity of EVs. We present a chromatographic method development based on preferential exclusion principle that can be used for EV isolation from adherent and microcarrier-based upstream. The method employs monolithic hydroxyl columns to purify and concentrate MSC-EVs. The heterogeneity in EV size and composition poses challenges in upstream and downstream processes; therefore, process development was guided by PATfix biochromatography analytics, tracking EV-specific surface antigens. The developed purification method enables direct concentration of MSC-EVs from conditioned media while removing 97% of protein impurities and 95% of double-stranded deoxyribonucleic acid (dsDNA)-related impurities in the process.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.